Pontault-Combault, France

Josef Aszodi

This inventor holds 1 USPTO granted patent. Top assignee: Deinove. Active years: 2019.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Josef Aszodi

Introduction

Josef Aszodi is a notable inventor based in Pontault-Combault, France. He has made significant contributions to the field of antimicrobial agents through his innovative research and development. His work focuses on a new class of compounds that have the potential to revolutionize the treatment of infections.

Latest Patents

Josef Aszodi holds a patent for a bicyclic lipolantipeptide, which is a novel antimicrobial agent. This invention represents a new class of lantipeptide and includes salts derived from it. The preparation of this compound is achieved through culturing specific microorganisms. The primary application of this invention is in the prevention and treatment of infections in humans, animals, or plants.

Career Highlights

Aszodi is currently associated with Deinove, a company known for its innovative approaches in biotechnology. His work at Deinove has allowed him to explore the potential of his inventions in practical applications. With a focus on antimicrobial solutions, he aims to address critical health challenges.

Collaborations

Josef Aszodi collaborates with talented individuals such as Dominique Le Beller and Guillaume Lesquame. These partnerships enhance the research and development process, leading to more effective solutions in the field of antimicrobial agents.

Conclusion

Josef Aszodi's contributions to the field of antimicrobial agents through his innovative inventions highlight the importance of research in combating infections. His work not only showcases his expertise but also emphasizes the potential impact of his inventions on public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…